Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Declan G Murphy

Showing results (71-80 of 414) with videos related to

Pageof 42
Sort By:
Current Opinion in Urology|November 15, 2019
Chemotherapy, not androgen receptor-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer. CON: Novel oral agents provide an attractive alternative to chemotherapy in metastatic hormone-sensitive prostate cancerBenjamin Condon, Grace Liskaser, Isaac A Thangasamy, et al.
BJU International|June 17, 2017
Prostate-specific membrane antigen radioguided surgery: a promising utilityNicolas Geurts, Alastair D Lamb, Nathan Lawrentschuk, et al.
Theranostics|June 23, 2017
PSMA-PET for Lymph Node Detection in Recurrent Prostate Cancer: How do we use the Magic Bullet?Tobias Maurer, Declan G Murphy, Michael S Hofman, et al.
BJU International|March 12, 2011
Early oncological outcomes of robot-assisted radical prostatectomy for high-grade prostate cancerPaul Cathcart, Stephen Connolly, Declan G Murphy, et al.
European Urology|March 25, 2017
Re: Radiation With or Without Antiandrogen Therapy in Recurrent Prostate CancerBenjamin W Lamb, John Violet, Shankar Siva, et al.
BJU International|February 18, 2009
High-intensity focused ultrasound for localized prostate cancer: initial experience with a 2-year follow-upBenjamin J Challacombe, Declan G Murphy, Rhana Zakri, et al.
European Urology Oncology|March 25, 2022
Re: Armando Stabile, Antony Pellegrino, Elio Mazzone, et al. Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard. Eur Urol Oncol 2022;5:1-17Kenneth Chen, Jonathan O'Brien, Aoife McVey, et al.
European Urology|July 30, 2019
Re: PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients with Metastatic Castration-resistant Prostate CancerDaniel McLennan, Niranjan Sathianathen, Omar Alghazo, et al.
Prostate International|March 30, 2026
Utilization of prostate-specific membrane antigen positron emission tomography in Australia following government subsidization: Trends in primary staging and biochemical recurrenceKieran Sandhu, Sean Lim, Nathan Lawrentschuk, et al.
Australian Journal of General Practice|June 30, 2021
Assessment and management of haematuria in the general practice settingEllen O'Connor, Aoife McVey, Stephanie Demkiw, et al.
Pageof 42

Showing results (71-80 of 414) with videos related to

Sort By:
Pageof 42
Current Opinion in Urology|November 15, 2019
Chemotherapy, not androgen receptor-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer. CON: Novel oral agents provide an attractive alternative to chemotherapy in metastatic hormone-sensitive prostate cancerBenjamin Condon, Grace Liskaser, Isaac A Thangasamy, et al.
BJU International|June 17, 2017
Prostate-specific membrane antigen radioguided surgery: a promising utilityNicolas Geurts, Alastair D Lamb, Nathan Lawrentschuk, et al.
Theranostics|June 23, 2017
PSMA-PET for Lymph Node Detection in Recurrent Prostate Cancer: How do we use the Magic Bullet?Tobias Maurer, Declan G Murphy, Michael S Hofman, et al.
BJU International|March 12, 2011
Early oncological outcomes of robot-assisted radical prostatectomy for high-grade prostate cancerPaul Cathcart, Stephen Connolly, Declan G Murphy, et al.
European Urology|March 25, 2017
Re: Radiation With or Without Antiandrogen Therapy in Recurrent Prostate CancerBenjamin W Lamb, John Violet, Shankar Siva, et al.
BJU International|February 18, 2009
High-intensity focused ultrasound for localized prostate cancer: initial experience with a 2-year follow-upBenjamin J Challacombe, Declan G Murphy, Rhana Zakri, et al.
European Urology Oncology|March 25, 2022
Re: Armando Stabile, Antony Pellegrino, Elio Mazzone, et al. Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard. Eur Urol Oncol 2022;5:1-17Kenneth Chen, Jonathan O'Brien, Aoife McVey, et al.
European Urology|July 30, 2019
Re: PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients with Metastatic Castration-resistant Prostate CancerDaniel McLennan, Niranjan Sathianathen, Omar Alghazo, et al.
Prostate International|March 30, 2026
Utilization of prostate-specific membrane antigen positron emission tomography in Australia following government subsidization: Trends in primary staging and biochemical recurrenceKieran Sandhu, Sean Lim, Nathan Lawrentschuk, et al.
Australian Journal of General Practice|June 30, 2021
Assessment and management of haematuria in the general practice settingEllen O'Connor, Aoife McVey, Stephanie Demkiw, et al.
Pageof 42